Clinical trial
Safety and Efficacy of T Cell Genetic Immunotherapy for HIV
NCT00131560 · VIRxSYS Corporation, Industry · Unknown status
Key facts
| NCT number | NCT00131560 |
|---|---|
| Title | Safety and Efficacy of T Cell Genetic Immunotherapy for HIV |
| Official title | A Phase II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Biological Activity of Single and Repeated Doses of Autologous T Cells Transduced With VRX496 in HIV-Positive Subjects |
| Lead sponsor | VIRxSYS Corporation, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infection |
| Intervention type | Genetic |
| Interventions | VRX496-Modified Autologous T cells |
| Enrollment | 60 |
| Start date | Jul 1, 2005 |
| Primary completion | Nov 1, 2008 |
| Completion | Jun 1, 2023 |
| First posted | Aug 18, 2005 |
| Last update posted | Jun 8, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: